Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  
June 27, 2024 10:30 ET | BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...
c+r-logo.png
Catch+Release Celebrates Major Wins at the 2024 Telly Awards
June 03, 2024 09:00 ET | Catch+Release
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Catch+Release, the leading content licensing marketplace, proudly announces its remarkable achievements at the 2024 Telly Awards. The company has...
Gastroenterologists
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET | Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
logo.png
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
March 18, 2024 07:28 ET | Arch Biopartners
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients...
July 30, 2021 - ROSEN LOGO.jpg
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
March 07, 2024 15:09 ET | The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Final Logo-01.png
PARP Inhibitor Market to Surpass USD 67.0 Billion by 2034, with 18.30% CAGR and Redefining Cancer Treatment Landscape - By PMI
February 27, 2024 14:30 ET | PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the PARP Inhibitor Market size was valued at about USD 12.5 Billion in 2024 and expected to grow at CAGR of 18.30%...
Charting New Paths:
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
February 23, 2024 13:50 ET | Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Final Logo-01.png
Biopharmaceutical and Biomedicine Market Size & Share to Exceed USD 1803.2 Billion by 2034, at CAGR of 12.20%. “Harnessing the Power of Genomics for Precision Medicine"– By PMI
February 12, 2024 19:30 ET | PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Biopharmaceutical and Biomedicine Market size was valued at about USD 570.0 Billion in 2024 and expected to...
Final Logo-01.png
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
February 08, 2024 17:30 ET | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Complex Disease Treatment Market Size & Share to Exceed USD 748.5 billion by 2034, at CAGR of 13.1%. Overview, Analysis, Dynamics, Report, Trend/Opportunities, Segmentation, Players, Growth Rate/Value - By PMI
February 01, 2024 13:00 ET | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Complex Disease Treatment Market size was valued at about USD 244.4 billion in 2024 and expected to grow at...